Literature DB >> 19587525

Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism.

Fulvio Chiacchiera1, Cristiano Simone.   

Abstract

Autophagy is an essential process for the maintenance of cellular and metabolic homeostasis. Indeed, it is required for the recovery of ATP-generating substrates in cells subjected to different types of stress insults. Thus, the activity of the autophagic machinery strongly depends on the metabolic status of the cell.(1) It has been proposed that this principle applies not only to normal, but also to cancer cells,(2) despite the profound differences in their metabolism. Cancer cells predominantly produce ATP through the constitutive activation of aerobic glycolysis, a process that generally relies on the stabilization and activation of the transcription factor HIF1alpha, which regulates the expression of glycolytic genes.(3) We recently showed that p38alpha is required to sustain the expression of HIF1alpha target genes, and that its inhibition causes a rapid drop in ATP levels in colorectal cancer cells (CRCs). This acute energy need triggers AMPK-dependent nuclear accumulation of FoxO3A and subsequent activation of its transcriptional program, leading to sequential induction of autophagy, cell cycle arrest and cell death. In vivo, pharmacological blockade of p38alpha has both a cytostatic and cytotoxic effect on colorectal neoplasms, associated with nuclear enrichment of FoxO3A and expression of its target genes p21 and PTEN.(4) Our data suggest that CRCs impaired in their glycolytic metabolism trigger autophagy as a reversible recovery mechanism and undergo cell cycle arrest; however, the persistence of the stress insults inevitably leads to cell death.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587525     DOI: 10.4161/auto.5.7.9252

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  38 in total

Review 1.  Mitochondria and FOXO3 in stem cell homeostasis, a window into hematopoietic stem cell fate determination.

Authors:  Raymond Liang; Saghi Ghaffari
Journal:  J Bioenerg Biomembr       Date:  2017-06-21       Impact factor: 2.945

Review 2.  MYC and tumor metabolism: chicken and egg.

Authors:  Francesca R Dejure; Martin Eilers
Journal:  EMBO J       Date:  2017-11-10       Impact factor: 11.598

3.  Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

Authors:  Valentina Grossi; Giuseppe Lucarelli; Giovanna Forte; Alessia Peserico; Antonio Matrone; Aldo Germani; Monica Rutigliano; Alessandro Stella; Rosanna Bagnulo; Daria Loconte; Vanessa Galleggiante; Francesca Sanguedolce; Simona Cagiano; Pantaleo Bufo; Senia Trabucco; Eugenio Maiorano; Pasquale Ditonno; Michele Battaglia; Nicoletta Resta; Cristiano Simone
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

Review 4.  The Lacritin-Syndecan-1-Heparanase Axis in Dry Eye Disease.

Authors:  Karina Dias-Teixeira; Xavier Horton; Robert McKown; Jeffrey Romano; Gordon W Laurie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 5.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a.

Authors:  Ashish Saxena; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Antioxid Redox Signal       Date:  2012-10-25       Impact factor: 8.401

7.  Autophagy regulation in cancer development and therapy.

Authors:  Erin J White; Vanesa Martin; Juinn-Lin Liu; Sarah R Klein; Sujan Piya; Candelaria Gomez-Manzano; Juan Fueyo; Hong Jiang
Journal:  Am J Cancer Res       Date:  2010-01-25       Impact factor: 6.166

8.  A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels.

Authors:  Alessia Peserico; Fulvio Chiacchiera; Valentina Grossi; Antonio Matrone; Dominga Latorre; Marta Simonatto; Aurora Fusella; James G Ryall; Lydia W S Finley; Marcia C Haigis; Gaetano Villani; Pier Lorenzo Puri; Vittorio Sartorelli; Cristiano Simone
Journal:  Cell Mol Life Sci       Date:  2013-01-03       Impact factor: 9.261

9.  BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

Authors:  Sara Samuel; Vladimir Beljanski; Julien Van Grevenynghe; Stephanie Richards; Fethia Ben Yebdri; Zhong He; Carmen Nichols; S Mehdi Belgnaoui; Courtney Steel; Marie-Line Goulet; April Shamy; Dawn Brown; Guillermo Abesada; Elias K Haddad; John Hiscott
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

10.  Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.

Authors:  Valentina Grossi; Micaela Liuzzi; Stefania Murzilli; Nicola Martelli; Anna Napoli; Giuseppe Ingravallo; Alberto Del Rio; Cristiano Simone
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.